Bill Few Associates Inc. Trims Position in Gilead Sciences, Inc. $GILD

Bill Few Associates Inc. lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 25.3% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,954 shares of the biopharmaceutical company’s stock after selling 1,000 shares during the quarter. Bill Few Associates Inc.’s holdings in Gilead Sciences were worth $328,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC purchased a new stake in Gilead Sciences during the first quarter valued at $25,000. Activest Wealth Management grew its position in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Goodman Advisory Group LLC purchased a new stake in shares of Gilead Sciences during the first quarter worth about $29,000. Colonial Trust Advisors grew its position in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares in the last quarter. Finally, Core Alternative Capital grew its position in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 241 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the sale, the chief financial officer directly owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. This trade represents a 1.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares of the company’s stock, valued at $66,013,726.98. This represents a 1.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 77,000 shares of company stock valued at $8,853,430. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $117.18 on Monday. The stock has a market capitalization of $145.40 billion, a PE ratio of 23.34, a P/E/G ratio of 0.80 and a beta of 0.34. The business has a 50 day simple moving average of $114.65 and a two-hundred day simple moving average of $110.25. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 1-year low of $84.17 and a 1-year high of $121.83.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on GILD. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a research report on Tuesday, August 19th. Cantor Fitzgerald increased their target price on Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a research report on Thursday. Royal Bank Of Canada increased their target price on Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 8th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $118.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.